Need Assistance?

US & Canada:
+
UK: +

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

Neuropeptide K (human, porcine, rat)

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Neuropeptide K (human, porcine, rat), a brain tachykinin, is a major tachykinin in plasma and tumor tissues of carcinoid patients.

Category

Peptide Inhibitors

Catalog number

BAT-015120

CAS number

96827-05-3

Molecular Formula

C175H284N52O52S

Molecular Weight

3980.57

Specification
Reference Reading

IUPAC Name

(4S)-5-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]propanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoic acid

Synonyms

Neuropeptide K, porcine; H-Asp-Ala-Asp-Ser-Ser-Ile-Glu-Lys-Gln-Val-Ala-Leu-Leu-Lys-Ala-Leu-Tyr-Gly-His-Gly-Gln-Ile-Ser-His-Lys-Arg-His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2; Neuropeptide K (swine); L-alpha-aspartyl-L-alanyl-L-alpha-aspartyl-L-seryl-L-seryl-L-isoleucyl-L-alpha-glutamyl-L-lysyl-L-glutaminyl-L-valyl-L-alanyl-L-leucyl-L-leucyl-L-lysyl-L-alanyl-L-leucyl-L-tyrosyl-glycyl-L-histidyl-glycyl-L-glutaminyl-L-isoleucyl-L-seryl-L-histidyl-L-lysyl-L-arginyl-L-histidyl-L-lysyl-L-threonyl-L-alpha-aspartyl-L-seryl-L-phenylalanyl-L-valyl-glycyl-L-leucyl-L-methioninamide; NPK (human, porcine, rat)

Appearance

White Lyophilized Powder

Purity

≥95%

Sequence

DADSSIEKQVALLKALYGHGQISHKRHKTDSFVGLM-NH2

Storage

Store at -20°C

Solubility

Soluble in Water

InChI

InChI=1S/C175H284N52O52S/c1-22-91(15)139(226-169(274)127(81-231)221-168(273)125(79-229)220-163(268)122(70-135(243)244)212-143(248)93(17)196-146(251)103(180)69-134(241)242)172(277)209-112(49-52-133(239)240)153(258)203-106(39-28-32-55-177)151(256)208-111(48-51-129(182)235)156(261)224-138(90(13)14)171(276)198-95(19)145(250)211-114(61-86(5)6)159(264)213-116(63-88(9)10)158(263)205-105(38-27-31-54-176)149(254)197-94(18)144(249)210-115(62-87(7)8)160(265)214-117(65-98-43-45-102(233)46-44-98)147(252)190-76-131(237)201-119(66-99-72-186-82-193-99)148(253)191-75-130(236)199-110(47-50-128(181)234)155(260)225-140(92(16)23-2)173(278)222-126(80-230)167(272)217-121(68-101-74-188-84-195-101)162(267)206-107(40-29-33-56-178)150(255)204-109(42-35-58-189-175(184)185)152(257)216-120(67-100-73-187-83-194-100)161(266)207-108(41-30-34-57-179)154(259)227-141(96(20)232)174(279)218-123(71-136(245)246)164(269)219-124(78-228)166(271)215-118(64-97-36-25-24-26-37-97)165(270)223-137(89(11)12)170(275)192-77-132(238)200-113(60-85(3)4)157(262)202-104(142(183)247)53-59-280-21/h24-26,36-37,43-46,72-74,82-96,103-127,137-141,228-233H,22-23,27-35,38-42,47-71,75-81,176-180H2,1-21H3,(H2,181,234)(H2,182,235)(H2,183,247)(H,186,193)(H,187,194)(H,188,195)(H,190,252)(H,191,253)(H,192,275)(H,196,251)(H,197,254)(H,198,276)(H,199,236)(H,200,238)(H,201,237)(H,202,262)(H,203,258)(H,204,255)(H,205,263)(H,206,267)(H,207,266)(H,208,256)(H,209,277)(H,210,249)(H,211,250)(H,212,248)(H,213,264)(H,214,265)(H,215,271)(H,216,257)(H,217,272)(H,218,279)(H,219,269)(H,220,268)(H,221,273)(H,222,278)(H,223,270)(H,224,261)(H,225,260)(H,226,274)(H,227,259)(H,239,240)(H,241,242)(H,243,244)(H,245,246)(H4,184,185,189)/t91-,92-,93-,94-,95-,96+,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,137-,138-,139-,140-,141-/m0/s1

InChI Key

JQFXXAVTGRUYHE-SAJHPLQRSA-N

Canonical SMILES

CCC(C)C(C(=O)NC(CO)C(=O)NC(CC1=CN=CN1)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC2=CN=CN2)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)NC(CO)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)N)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CC4=CN=CN4)NC(=O)CNC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCCCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(C)NC(=O)C(CC(=O)O)N

1. Tachykinins and calcitonin gene-related peptide: co-existence in sensory nerves of the nasal mucosa and effects on blood flow

J M Lundberg, A Anggård, P Stjärne, L Lundblad, T Hökfelt Cell Tissue Res . 1989 Jun;256(3):439-46. doi: 10.1007/BF00225591.

The presence and co-existence of calcitonin gene-related peptide (CGRP)- and substance P (SP)-like immunoreactivity (-LI) in sensory neurons of the nasal mucosa and trigeminal ganglion in several vertebrate species, including man, were established using immunohistochemistry. In the nasal mucosa the CGRP- and SP-immunoreactive (IR) nerve fibers were localized within the epithelium, around arteries, arterioles, venules, venous sinusoids and close to exocrine elements, mainly ducts. Double-staining experiments revealed that the CGRP-LI-containing nerve profiles and cell bodies also contained SP-LI. In the pig, CGRP- and SP-IR fibers were also detected in the maxillary portion of the trigeminal nerve and around the sphenopalatine artery and vein, as well as around the nasal dorsal vein. The nasal mucosal content of CGRP-LI, as determined by radioimmunoassay, was almost 5-fold higher in the pig and guinea pig compared to man. The nasal CGRP-IR nerves disappeared after capsaicin pretreatment in the guinea pig. In the cat, local intra-arterial infusions of capsaicin, SP, neurokinin A (NKA), neuropeptide K (NPK) and CGRP caused a concentration-dependent increase in nasal blood flow. CGRP caused a longer-lasting vasodilatation than the tachykinins. In conclusion, the morphological findings of co-localization of CGRP-LI and SP-LI in capsaicin-sensitive nerve fibers of the nasal mucosa and trigeminal ganglia of different species including man, coupled with the in vivo description of the high vasodilator potency of CGRP and tachykinins, imply co-release of several vasoactive agents upon activation of the nasal sensory nerves. Furthermore, the similarity of the morphological findings among the different species indicates that experimental data from animals may reflect the existence of similar mechanisms in humans.